Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hepatitis b drug shows promise in early safety trial

NCT ID NCT03365947

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 25 times

Summary

This study tested an experimental drug called ARO-HBV in 114 people, including healthy volunteers and patients with chronic hepatitis B. The main goal was to check if the drug is safe and how the body processes it. Researchers gave single or multiple doses and monitored side effects and drug levels. This is an early-stage trial, so it focuses on safety rather than a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Research Site 1

    Grafton, Auckland, 1010, New Zealand

  • Research Site 2

    Papatoetoe, Auckland, 2025, New Zealand

  • Research Site 3

    Melbourne, Victoria, 3065, Australia

  • Research Site 4

    Clayton, Victoria, 3168, Australia

  • Research Site 5

    Camperdown, New South Wales, 2050, Australia

  • Research Site 6

    Nedlands, Western Australia, 6009, Australia

  • Research Site 7

    Hong Kong, Hong Kong

Conditions

Explore the condition pages connected to this study.